Arcellx shares are trading lower after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial.
Portfolio Pulse from Benzinga Newsdesk
The FDA has placed a clinical hold on Arcellx's multiple myeloma phase 2 trial, causing the company's shares to trade lower.
June 20, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcellx's shares are trading lower due to the FDA's clinical hold on the company's multiple myeloma phase 2 trial.
The FDA's decision to place a clinical hold on Arcellx's multiple myeloma phase 2 trial directly impacts the company's progress and potential revenue from the trial. This negative news has caused the company's shares to trade lower, indicating a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100